1Barker FG Ⅱ, Chang SM, Gutin PH, et al . Survival and functional status after resection of recurrent glioblastoma multiforme [J]. Neurosurgery, 1998, 42: 709～723.
2Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain [J]. J Neurosurg, 1997, 86: 525～531.
3Badie B, Goh CS, Klaver J, et al. Combined radiation and p53 gene therapy of malignant glioma cells [J]. Cancer Gene Ther, 1999, 6: 155～162.
4Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131Ⅰ: Comparison of the results obtained in recurrent and newly diagnosed tumors [J]. Cancer Res, 1995, 55 (Suppl): 5952～5956.
5Jain RK. Delivery of novel therapeutic agents in tumors:Physiologic barriers and strategies [J]. J Natl Cancer Inst,1989, 81: 570～576.
6Bobo RH, Laske DW, Akbasak A, et al . Convection-enhanced delivery of macromolecules in the brain [J]. Proc Natl Acad Sci USA, 1994, 91: 2076～2080.
7Lieberman DM, Laske DW, Morrison PF, et al . Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion [J]. J Neurosurg, 1995,82: 1021～1029.
8Chen MY, Lonser RR, Morrison PF, et al. Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time [J]. J Neurosurg, 1999, 90: 315～320.
9Kroll RA, Pagel MA, Muldoon LL, et al. Increasing volume of distribution to the brain with interstitial infusion: dose,rather than convection, might be the most important factor[J]. Neurosurgery, 1996, 38: 746～754.
10Laske DW, Morrison PF, Lieberman DM, et al . Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging [J]. J Neurosurg, 1997, 87: 586～594.
